| Title |
Drug Repurposing in Parkinson’s Disease
|
|---|---|
| Published in |
CNS Drugs, July 2018
|
| DOI | 10.1007/s40263-018-0548-y |
| Pubmed ID | |
| Authors |
Dilan Athauda, Thomas Foltynie |
| Abstract |
The development of an intervention to slow or halt disease progression remains the greatest unmet therapeutic need in Parkinson's disease. Given the number of failures of various novel interventions in disease-modifying clinical trials in combination with the ever-increasing costs and lengthy processes for drug development, attention is being turned to utilizing existing compounds approved for other indications as novel treatments in Parkinson's disease. Advances in rational and systemic drug repurposing have identified a number of drugs with potential benefits for Parkinson's disease pathology and offer a potentially quicker route to drug discovery. Here, we review the safety and potential efficacy of the most promising candidates repurposed as potential disease-modifying treatments for Parkinson's disease in the advanced stages of clinical testing. |
X Demographics
The data shown below were collected from the profiles of 19 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 6 | 32% |
| United States | 3 | 16% |
| Australia | 2 | 11% |
| Switzerland | 1 | 5% |
| Unknown | 7 | 37% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 12 | 63% |
| Practitioners (doctors, other healthcare professionals) | 4 | 21% |
| Scientists | 3 | 16% |
Mendeley readers
The data shown below were compiled from readership statistics for 96 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 96 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 18 | 19% |
| Student > Ph. D. Student | 14 | 15% |
| Researcher | 10 | 10% |
| Student > Bachelor | 7 | 7% |
| Student > Postgraduate | 3 | 3% |
| Other | 6 | 6% |
| Unknown | 38 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 19 | 20% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 14% |
| Neuroscience | 7 | 7% |
| Medicine and Dentistry | 6 | 6% |
| Chemistry | 5 | 5% |
| Other | 6 | 6% |
| Unknown | 40 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 August 2019.
All research outputs
#2,767,216
of 25,617,409 outputs
Outputs from CNS Drugs
#230
of 1,395 outputs
Outputs of similar age
#53,499
of 341,410 outputs
Outputs of similar age from CNS Drugs
#6
of 27 outputs
Altmetric has tracked 25,617,409 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,395 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.7. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,410 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.